 I. To determine the feasibility, tolerability, and toxicities of ABT-888 veliparib when administered alone and in combination with topotecan hydrochloride with or without carboplatin in patients with relapsed or refractory acute leukemia, high-risk myelodysplasia, or aggressive myeloproliferative disorders. 